<DOC>
	<DOCNO>NCT00002325</DOCNO>
	<brief_summary>To compare efficacy fluconazole versus placebo prevent development active coccidioidomycosis systemic fungal infection among HIV-infected patient CD4 lymphocyte count &lt; 250 cells/mm3 live coccidioidal endemic area .</brief_summary>
	<brief_title>A Study Fluconazole Prevention Fungal Infections HIV-Infected Patients Living Areas Where Fungal Infections Are Common</brief_title>
	<detailed_description>Patients randomize receive either fluconazole placebo daily .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Coccidioidomycosis</mesh_term>
	<mesh_term>Coccidiosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 count &lt; 250 cells/mm3 . No active coccidioidomycosis fungal disease require systemic antifungal therapy . Residence area consider endemic Coccidioides immitis . Consent parent guardian legal age consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Unable take oral medication . Positive serum cryptococcal antigen . Concurrent Medication : Excluded : Systemic antifungal therapy . Patients follow prior condition exclude : History hypersensitivity azole imidazole compound . Prior Medication : Excluded : Systemic antifungal agent within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Mycoses</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Coccidioidomycosis</keyword>
</DOC>